TOKYO, Oct. 31, 2025 /PRNewswire/ -- Alpha Fusion Inc. (Headquarters: Chiyoda-ku, Tokyo; CEO: Sunao Fujioka; hereinafter "Alpha Fusion") today announced the initiation of a company-sponsored Phase I ...
SK Biopharmaceuticals said Monday it has received US Food and Drug Administration approval to begin a phase 1 clinical trial ...
Radiation Research, Vol. 152, No. 6, Supplement: The International Workshop on the Health Effects of Thorotrast, Radium, Radon and Other Alpha-Emitters 1999 (Dec., 1999), pp. S43-S47 (5 pages) There ...
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The ...
Researchers at Kanazawa University report in ACS Omega a promising combination of radioisotope-carrying molecules for use in radiotheranostics — a diagnosis-and-treatment approach based on the ...
The MarketWatch News Department was not involved in the creation of this content. -- Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naïve patients with ...
– Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naïve patients with differentiated thyroid cancer – This clinical trial is designed based on the results of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback